<DOC>
	<DOCNO>NCT00298688</DOCNO>
	<brief_summary>The purpose study determine disease control rate trial closure first stage study patient relapse refractory SCLC measurable disease treat gefitinib</brief_summary>
	<brief_title>A Study IRESSA Relapsed Refractory Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Provision write informed consent Histologically confirm , relapse refractory SCLCr Aged 18 life expectancy 2 month Any evidence clinically active interstitial lung disease Other coexist malignancy malignancy diagnose within last 5 year , exception basal cell carcinoma cervical cancer situ .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>